摘要
目的了解重组人粒细胞刺激因子(rhG-CSF)以及聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)在肿瘤患者的使用现状,为降低患者粒细胞减少伴发热相关临床事件的发生,提高(PEG-) rhG-CSF的合理使用率。方法随机抽取2018年上半年湖南省肿瘤医院180例次使用(PEG-) rhG-CSF的病例进行点评,分析其药物使用情况。结果该院rhG-CSF不合理用药类型排名前3位的依次是:用药疗程不适宜(56%)、用药时机不适宜(32%)、用量不适宜(23%);该院PEG-rhG-CSF不合理使用情况主要包括:用量不适宜,使用剂量偏小(66%)、用药时机不适宜(19%)、适应证不适宜(无高风险因素预防该药)(5%)。(PEG-) rhG-CSF应用总合理率仅6.1%。结论临床药师需提高化疗对骨髓抑制的认识,对患者进行全面评估,及早进行预防治疗,对于发生骨髓抑制的患者,应尽早进行升血象治疗,普及rhG-CSF药理及药代动力学的知识。
【Objective】 To make a rationale for the clinical therapy with recombinant human granulocyte colony stimulating factor(rhG-CSF) and PEG-rhG-CSF by analyzing clinical uses of(PEG) rhG-CSF medicines. 【Methods】 One hundred and eighty inpatient medical records were randomly selected from our hospital during the first half of the year 2018. Those medical records were commented and irrational ones were analyzed. 【Results】 Among 180 medical records, the total qualified rate was only 6.1%.Top 3 types of irrational drug use in rhG-CSF were unsuitable drug treatment(56%), unsuitable medication timing(32%), unsuitable dosage(23%). Top 3 types of irrational drug use in PEG-rhG-CSF were unsuitable dosage(66%), unsuitable medication timing(19%), and unsuitable drug treatment(5%). 【Conclusion】 It’s important for clinical pharmacists to strengthen administration for growth factors in our hospital so as to reduce the irrational use of rhG-CSF.
作者
龚倩
谌赟
刘妮
符一岚
何奕
GONG Qian;CHENYun;LIU Ni;FU Yilan;HE Yi(Pharmacy Department,Hunan Cancer Hospital(the Affiliated Hospital of Xiangya School of Medicine,Central South University);Head and Neck Oncology Department,Hunan Cancer Hospital(the Affiliated Hospital of Xiangya School of Medicine,Central South University))
出处
《中国医学工程》
2020年第8期11-14,共4页
China Medical Engineering
关键词
肿瘤
重组人粒细胞刺激因子
聚乙二醇化重组人粒细胞刺激因子
合理用药
用药分析
cancer
recombinant human granulocyte colony stimulating factor
pegylated recombinant human granulocyte colony stimulating factor
rational drug use
analysis of drug use
